Human Herpesvirus-6 in Hematopoietic Stem Cell Transplant Recipients: a Prospective Cohort Study in Egypt

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2023 Feb 4

PMID 36739398

Authors

May Moheb Eldin Raouf

Nancy Mohammed Ouf

Manal Abdel Sattar Elsorady

Faika Mahmoud Ghoneim

Affiliations

Soon will be listed here.

Abstract

Background: Immunocompromised patients face reactivation of latent viruses that increase the risk of morbidity.

Aim: The study aimed to detect human herpes virus 6 (HHV-6) reactivation among allogeneic (allo) and autologous (auto) hematopoietic stem cell transplant (HSCT) recipients and to correlate potentially attributed clinical manifestations to HHV-6 DNA plasma level.

Methods: A prospective study included all (forty) patients undergoing allo and auto-HSCT from Jan 2020 till June 2022. Plasma samples were collected for HHV-6 serology, and for HHV-6 quantitative PCR at post-transplantation weeks 2, 4, 6. Demographic and clinical data were recorded.

Results: Out of 40 peripheral blood stem cell transplant (PBSCT) recipients, 34 (85%) were HHV-6 IgG positive pre-HSCT. Of which, fourteen patients (14/34, 41.2%) showed positive HHV-6 DNaemia. HHV-6 DNAemia (15/40, 37.5%) was significantly higher among allo (8/12, 66.7%) versus auto (7/28, 25%) HSCT recipients (p = 0.030). Patients with HHV-6 DNAemia developed fever, delayed engraftment and bone marrow suppression in 6/15, 40%, thrombocytopenia (5/15, 33.3%), rash and pneumonitis (2/15, 13.3%), acute GVHD (aGVHD) (1/15, 6.7%). HHV-6 DNAemia ranged from 101 to 102,000 copies/mL. Univariate analysis identified conditioning with busulfan-cyclophosphamide as a significant risk (p = 0.043), while receiving BEAM protocol was a protective factor (p = 0.045). In multivariate analysis, receiving BEAM protocol retained significance (p = 0.040).

Conclusion: Frequent HHV-6 reactivation was detected after HSCT, especially in allo-HSCT recipients with clinical manifestations which could not be otherwise explained. To our best knowledge this is the first study of HHV6 reactivation in HSCT recipients from Egypt. Raising awareness for HHV-6 reactivation manifestations and screening in HSCT recipients could be lifesaving.

Citing Articles

M1 enrichment facilitates virus detection in patients with allogeneic hematopoietic stemcell transplantation.

Zheng H, Li S, Liang Z, Feng R, Lu J, Dong Y Medicine (Baltimore). 2025; 104(9):e41683.

PMID: 40020100 PMC: 11875608. DOI: 10.1097/MD.0000000000041683.

Performance evaluation of the SMG HHV-6 Q Real-Time PCR Kit for quantitative detection and differentiation of human herpesvirus 6A and 6B.

Kim T, Park M, Yun S, Kang M, Kim D, Shin A Microbiol Spectr. 2024; 12(4):e0424923.

PMID: 38451228 PMC: 10986541. DOI: 10.1128/spectrum.04249-23.

References

Zerr D, Corey L, Kim H, Huang M, Nguy L, Boeckh M . Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005; 40(7):932-40. DOI: 10.1086/428060. View

Dulery R, Salleron J, Dewilde A, Rossignol J, Boyle E, Gay J . Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol Blood Marrow Transplant. 2012; 18(7):1080-9. DOI: 10.1016/j.bbmt.2011.12.579. View

Shargian-Alon L, Yahav D, Rozovski U, Dovrat S, Amitai I, Sela-Navon M . Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation - a single-center experience. Leuk Lymphoma. 2019; 60(9):2230-2236. DOI: 10.1080/10428194.2019.1576869. View

Piukovics K, Borbenyi Z, Rajda C, Csomor A, Deak J, Terhes G . Monitoring human herpesvirus-6 in patients with autologous stem cell transplantation. In Vivo. 2014; 28(6):1113-7. View

Yoshikawa T, Asano Y, Ihira M, Suzuki K, Ohashi M, Suga S . Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. J Infect Dis. 2002; 185(7):847-53. DOI: 10.1086/339411. View

Yamane A, Mori T, Suzuki S, Mihara A, Yamazaki R, Aisa Y . Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant. 2007; 13(1):100-6. DOI: 10.1016/j.bbmt.2006.09.003. View

Jeulin H, Agrinier N, Guery M, Salmon A, Clement L, Bordigoni P . Human herpesvirus 6 infection after allogeneic stem cell transplantation: incidence, outcome, and factors associated with HHV-6 reactivation. Transplantation. 2013; 95(10):1292-8. DOI: 10.1097/TP.0b013e318289958b. View

Yoshikawa T, Ihira M, Ohashi M, Suga S, Asano Y, Miyazaki H . Correlation between HHV-6 infection and skin rash after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001; 28(1):77-81. DOI: 10.1038/sj.bmt.1703099. View

Chapenko S, Trociukas I, Donina S, Chistyakov M, Sultanova A, Gravelsina S . Relationship between beta-herpesviruses reactivation and development of complications after autologous peripheral blood stem cell transplantation. J Med Virol. 2012; 84(12):1953-60. DOI: 10.1002/jmv.23412. View

10.

Iesato K, Hori T, Yoto Y, Yamamoto M, Inazawa N, Kamo K . Long-term prognosis of human herpesvirus 6 reactivation following allogeneic hematopoietic stem cell transplantation. Pediatr Int. 2018; 60(6):547-552. DOI: 10.1111/ped.13551. View

11.

Balsat M, Pillet S, Tavernier E, Cacheux V, Escuret V, Molucon-Chabrot C . Human herpesvirus 6 infection after autologous stem cell transplantation: A multicenter prospective study in adult patients. J Infect. 2019; 79(1):36-42. DOI: 10.1016/j.jinf.2019.05.001. View

12.

Miyoshi H, Tanaka-Taya K, Hara J, Fujisaki H, Matsuda Y, Ohta H . Inverse relationship between human herpesvirus-6 and -7 detection after allogeneic and autologous stem cell transplantation. Bone Marrow Transplant. 2001; 27(10):1065-70. DOI: 10.1038/sj.bmt.1703033. View

13.

Lanza F, Campioni D, Hellmann A, Milone G, Wahlin A, Walewski J . Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. Biol Blood Marrow Transplant. 2013; 19(12):1670-6. DOI: 10.1016/j.bbmt.2013.08.005. View

14.

Aoki J, Numata A, Yamamoto E, Fujii E, Tanaka M, Kanamori H . Impact of Human Herpesvirus-6 Reactivation on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015; 21(11):2017-22. DOI: 10.1016/j.bbmt.2015.07.022. View

15.

Zerr D, Boeckh M, Delaney C, Martin P, Xie H, Adler A . HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18(11):1700-8. PMC: 3439599. DOI: 10.1016/j.bbmt.2012.05.012. View

16.

Sashihara J, Tanaka-Taya K, Tanaka S, Amo K, Miyagawa H, Hosoi G . High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. Blood. 2002; 100(6):2005-11. View

17.

Inazawa N, Hori T, Nojima M, Saito M, Igarashi K, Yamamoto M . Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay. J Med Virol. 2016; 89(2):358-362. DOI: 10.1002/jmv.24621. View

18.

Kuhn . Transfusion-Associated Infections with Cytomegalovirus and Other Human Herpesviruses. Infusionsther Transfusionsmed. 2000; 27(3):138-143. DOI: 10.1159/000025258. View

19.

Ogata M, Satou T, Kadota J, Saito N, Yoshida T, Okumura H . Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study. Clin Infect Dis. 2013; 57(5):671-81. DOI: 10.1093/cid/cit358. View

20.

Winestone L, Punn R, Tamaresis J, Buckingham J, Pinsky B, Waggoner J . High human herpesvirus 6 viral load in pediatric allogeneic hematopoietic stem cell transplant patients is associated with detection in end organs and high mortality. Pediatr Transplant. 2017; 22(2). PMC: 5820136. DOI: 10.1111/petr.13084. View